<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839279</url>
  </required_header>
  <id_info>
    <org_study_id>ZAN-QT-1006</org_study_id>
    <nct_id>NCT01839279</nct_id>
  </id_info>
  <brief_title>A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial</brief_title>
  <acronym>TQT</acronym>
  <official_title>A Partial-Blind, Randomized, Parallel Design Study With a Nested Crossover Comparison to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study
      with a nested crossover comparison to define the ECG effects of tizanidine compared to
      placebo and the positive control, moxifloxacin, in healthy men and women. The study will be
      conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the
      protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.</measure>
    <time_frame>Baseline and Day 5</time_frame>
    <description>Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling</measure>
    <time_frame>Day 5, Day 14</time_frame>
    <description>The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 8, 12 &amp; 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 8, 12 &amp; 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 8, 12 &amp; 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Spasticity</condition>
  <arm_group>
    <arm_group_label>Tizanidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose of 2 and 4 milligram (mg) tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo followed by a single dose 400 mg moxifloxacin tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 400 mg moxifloxacin followed by placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tizanidine</intervention_name>
    <arm_group_label>Tizanidine</arm_group_label>
    <other_name>Zanaflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of childbearing potential should have a negative urine pregnancy test prior to
             Screening and Day -2 of the trial

          -  All subjects of childbearing potential must practice a highly effective method of
             birth control excluding oral contraceptives for the duration of the trial and up to 3
             months after the last dose of investigational product. Oral contraceptives are not
             allowed, based on the precaution listed in the Zanaflex package insert.

          -  Have a body mass index (BMI) ranging between 19 and 30 kg/m2

          -  Comprehend and be able to provide written informed consent

          -  Be willing and able to comply with all trial requirements

        Exclusion Criteria:

          -  Female who is either pregnant, breastfeeding or planning to become pregnant

          -  History of hypersensitivity or allergic reaction to tizanidine or moxifloxacin or any
             of the tablet components

          -  Any condition possibly affecting drug absorption, metabolism or excretion including
             previous surgery for removal of parts of stomach, bowel, liver, gall bladder, or
             pancreas

          -  History of Long QT Syndrome or a first-generation relative with this condition

          -  Evidence or history of clinically significant allergies except for untreated,
             asymptomatic, seasonal allergies at time of dosing, hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, or
             neurological disease. Determination of clinical significance is to be made at the
             Investigator's discretion

          -  History or presence of any malignant or benign neoplasm considered by the investigator
             to be clinically significant

          -  History of drug or alcohol abuse or dependence within the last year

          -  Have an active infectious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathews Adera, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance- Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <results_first_submitted>February 27, 2015</results_first_submitted>
  <results_first_submitted_qc>May 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2015</results_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tizanidine</title>
        </group>
        <group group_id="P2">
          <title>Initial Placebo and Crossover to Moxifloxacin</title>
          <description>Dosing of moxifloxacin will only be analyzed for cause (if the effect of moxifloxacin is not as expected).</description>
        </group>
        <group group_id="P3">
          <title>Initial Moxifloxacin and Crossover to Placebo</title>
          <description>Dosing of moxifloxacin will only be analyzed for cause (if the effect of moxifloxacin is not as expected).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>QT/QTc Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Moxifloxacin/Placebo Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK/QTc Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Classified as 'Other'</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Tizanidine</title>
        </group>
        <group group_id="B2">
          <title>Initial Placebo and Crossover to Moxifloxacin</title>
          <description>Dosing of moxifloxacin will only be analyzed for cause (if the effect of moxifloxacin is not as expected).</description>
        </group>
        <group group_id="B3">
          <title>Initial Moxifloxacin and Crossover to Placebo</title>
          <description>Dosing of moxifloxacin will only be analyzed for cause (if the effect of moxifloxacin is not as expected).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="6.75"/>
                    <measurement group_id="B2" value="34.1" spread="7.51"/>
                    <measurement group_id="B3" value="35.3" spread="7.21"/>
                    <measurement group_id="B4" value="34.0" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.</title>
        <description>Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.</description>
        <time_frame>Baseline and Day 14</time_frame>
        <population>QT/QTc Analysis set: Received at least 1 dose of study drug (including placebo), had measurements at baseline and on-treatment with at least 1 time point post-dose with at minimum triplicate measures giving rise to a QTc value for primary correction method. Effect of moxifloxacin was as expected. Therefore, no analysis required per Medical Monitor.</population>
        <group_list>
          <group group_id="O1">
            <title>Tizanidine 24 mg</title>
            <description>60 subjects Tizanidine 24 mg single dose</description>
          </group>
          <group group_id="O2">
            <title>Tizanidine Placebo 24 mg</title>
            <description>61 subjects placebo used for the analysis.</description>
          </group>
          <group group_id="O3">
            <title>Tizanidine 24 mg Placebo-corrected</title>
            <description>60 subjects Tizanidine 24 mg single dose, 61 subjects placebo used for the analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.</title>
          <description>Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.</description>
          <population>QT/QTc Analysis set: Received at least 1 dose of study drug (including placebo), had measurements at baseline and on-treatment with at least 1 time point post-dose with at minimum triplicate measures giving rise to a QTc value for primary correction method. Effect of moxifloxacin was as expected. Therefore, no analysis required per Medical Monitor.</population>
          <units>milliseconds (msec)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint (Hour) 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" lower_limit="-6.3" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-2.5" upper_limit="1.4"/>
                    <measurement group_id="O3" value="-3.7" lower_limit="-6.6" upper_limit="-0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-4.0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-0.8" upper_limit="3.2"/>
                    <measurement group_id="O3" value="-3.2" lower_limit="-6.0" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-6.0" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.6" upper_limit="4.5"/>
                    <measurement group_id="O3" value="-6.6" lower_limit="-9.4" upper_limit="-3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" lower_limit="-6.9" upper_limit="-2.6"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.6" upper_limit="4.8"/>
                    <measurement group_id="O3" value="-7.4" lower_limit="-10.5" upper_limit="-4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-5.6" upper_limit="-1.6"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.9" upper_limit="4.8"/>
                    <measurement group_id="O3" value="-6.4" lower_limit="-9.2" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-0.4" upper_limit="3.6"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.4" upper_limit="5.4"/>
                    <measurement group_id="O3" value="-1.8" lower_limit="-4.6" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-4.1" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.4" upper_limit="4.8"/>
                    <measurement group_id="O3" value="-5.5" lower_limit="-7.9" upper_limit="-3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.5" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.5" upper_limit="2.5"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-5.1" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-1.3" upper_limit="2.2"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.9" upper_limit="4.4"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-4.6" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.</title>
        <description>Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.</description>
        <time_frame>Baseline and Day 5</time_frame>
        <population>QT/QTc Analysis set: Received at least 1 dose of study drug (including placebo), had measurements at baseline and on-treatment with at least 1 time point post-dose with at minimum triplicate measures giving rise to a QTc value for primary correction method. Effect of moxifloxacin was as expected. Therefore, no analysis required per Medical Monitor.</population>
        <group_list>
          <group group_id="O1">
            <title>Tizanidine 8 mg</title>
            <description>70 subjects Tizanidine 8 mg single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tizanidine Placebo 8 mg</title>
            <description>63 subjects placebo used for analysis.</description>
          </group>
          <group group_id="O3">
            <title>Tizanidine 8 mg Placebo-corrected</title>
            <description>70 subjects Tizanidine 8 mg single dose, 63 subjects placebo used for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.</title>
          <description>Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.</description>
          <population>QT/QTc Analysis set: Received at least 1 dose of study drug (including placebo), had measurements at baseline and on-treatment with at least 1 time point post-dose with at minimum triplicate measures giving rise to a QTc value for primary correction method. Effect of moxifloxacin was as expected. Therefore, no analysis required per Medical Monitor.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint (Hour) 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-2.5" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-2.7" upper_limit="0.8"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-2.3" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.5" upper_limit="2.3"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-3.5" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.9" upper_limit="1.9"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.3" upper_limit="4.3"/>
                    <measurement group_id="O3" value="-2.3" lower_limit="-5.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.7" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-0.6" upper_limit="3.1"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-2.7" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.3" upper_limit="2.1"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-3.1" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.2" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.5" upper_limit="2.5"/>
                    <measurement group_id="O3" value="1.6" lower_limit="-0.4" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-3.1" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-1.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-4.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-1.6" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-0.9" upper_limit="2.3"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-3.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-0.1" upper_limit="3.0"/>
                    <measurement group_id="O3" value="-1.9" lower_limit="-4.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling</title>
        <description>The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.</description>
        <time_frame>Day 5, Day 14</time_frame>
        <population>Pk/QTc Analysis set will include all subjects in the QT/QTc analysis set with at least one valid PK assessment. Effect of moxifloxacin was as expected. Therefore, no analysis required per Medical Monitor.</population>
        <group_list>
          <group group_id="O1">
            <title>Tizanidine</title>
          </group>
        </group_list>
        <measure>
          <title>Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling</title>
          <description>The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.</description>
          <population>Pk/QTc Analysis set will include all subjects in the QT/QTc analysis set with at least one valid PK assessment. Effect of moxifloxacin was as expected. Therefore, no analysis required per Medical Monitor.</population>
          <units>msec per ng/mL</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1209" lower_limit="-0.1894" upper_limit="-0.0524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</title>
        <time_frame>0.5, 1, 1.5, 2, 4, 8, 12 &amp; 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)</time_frame>
        <population>PK Analysis set: all subjects from Group 1 who received at least one study drug and have at least one valid PK assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Day 5 (Tizanidine 8 mg)</title>
          </group>
          <group group_id="O2">
            <title>Day 14 (Tizanidine 24 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</title>
          <population>PK Analysis set: all subjects from Group 1 who received at least one study drug and have at least one valid PK assessment</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="43.9"/>
                    <measurement group_id="O2" value="27.4" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</title>
        <time_frame>0.5, 1, 1.5, 2, 4, 8, 12 &amp; 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)</time_frame>
        <population>PK Analysis set: all subjects from Group 1 who received at least one study drug and have at least one valid PK assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Day 5 (Tizanidine 8 mg)</title>
          </group>
          <group group_id="O2">
            <title>Day 14 (Tizanidine 24 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</title>
          <population>PK Analysis set: all subjects from Group 1 who received at least one study drug and have at least one valid PK assessment</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="0.600" upper_limit="4.10"/>
                    <measurement group_id="O2" value="2.10" lower_limit="0.600" upper_limit="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</title>
        <time_frame>0.5, 1, 1.5, 2, 4, 8, 12 &amp; 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)</time_frame>
        <population>PK Analysis set: all subjects from Group 1 who received at least one study drug and have at least one valid PK assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Day 5 (Tizanidine 8 mg)</title>
          </group>
          <group group_id="O2">
            <title>Day 14 (Tizanidine 24 mg)</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.</title>
          <population>PK Analysis set: all subjects from Group 1 who received at least one study drug and have at least one valid PK assessment</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="65.1"/>
                    <measurement group_id="O2" value="115" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 23 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tizanidine</title>
        </group>
        <group group_id="E2">
          <title>Initial Placebo and Crossover to Moxifloxacin</title>
        </group>
        <group group_id="E3">
          <title>Initial Moxifloxacin and Crossover to Placebo</title>
        </group>
        <group group_id="E4">
          <title>Placebo and Moxifloxacin Groups Combined</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Acorda Therapeutics, Inc.</organization>
      <phone>914-437-4300 ext 5263</phone>
      <email>paupperle@acorda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

